- Home
- TXN vs SNY Comparison
TXN vs SNY Comparison
Compare TXN & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TXN | SNY |
|---|---|---|
| Founded | 1930 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.8B | 119.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TXN | SNY |
|---|---|---|
| Price | $182.11 | $48.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 5 |
| Target Price | ★ $201.75 | $61.50 |
| AVG Volume (30 Days) | ★ 7.1M | 2.4M |
| Earning Date | 01-22-2026 | 01-29-2026 |
| Dividend Yield | 2.99% | ★ 3.31% |
| EPS Growth | 2.06 | ★ 105.93 |
| EPS | 5.49 | ★ 8.67 |
| Revenue | $17,266,000,000.00 | ★ $53,890,648,839.00 |
| Revenue This Year | $14.30 | $2.48 |
| Revenue Next Year | $8.03 | $6.47 |
| P/E Ratio | $33.09 | ★ $5.57 |
| Revenue Growth | ★ 9.90 | N/A |
| 52 Week Low | $139.95 | $44.62 |
| 52 Week High | $221.69 | $60.12 |
Technical Indicators
Market Signals| Indicator | TXN | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 65.90 | 40.01 |
| Support Level | $158.69 | $47.80 |
| Resistance Level | $184.76 | $49.73 |
| Average True Range (ATR) | 5.11 | 0.67 |
| MACD | 2.36 | -0.25 |
| Stochastic Oscillator | 90.88 | 16.04 |
Price Performance
Historical ComparisonAbout TXN Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.